# ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

> **NCT07188025** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 103 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT07188025
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2030-10
- **Final completion:** 2035-10
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188025, "ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07188025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*